Viking Therapeutics, Inc. (VKTX) latest stock news and headlines
This article provides a compilation of recent news and headlines concerning Viking Therapeutics, Inc. (VKTX) stock, including its performance relative to the market and updates on its obesity drug trials. It features several headlines from financial news outlets like Zacks and Simply Wall St., discussing stock dips, analyst opinions, and enrollment milestones for VK2735. The article also provides key financial data for VKTX and other market indicators.
Viking Therapeutics, Inc. (VKTX) Shares Fall as Broader Market Rises: Important Details
Viking Therapeutics (VKTX) shares fell by 2.5% to $33.93, contrasting with a broader market rise, though the stock has gained 5.52% over the last month. Analysts anticipate an EPS of -$1.01 for the upcoming quarter and a loss of $4.15 per share for the fiscal year, with no revenue. The company currently holds a Zacks Rank of #3 (Hold) within the Medical - Biomedical and Genetics industry.
Viking Therapeutics (VKTX) Is Up 7.0% After Completing Enrollment In Key VANQUISH-2 Obesity Trial
Viking Therapeutics (VKTX) has completed patient enrollment for its VANQUISH-2 Phase 3 trial of VK2735, a dual GLP-1/GIP agonist for obesity and type 2 diabetes. This milestone advances their lead candidate closer to pivotal data, building on previous positive Phase 2 results. The completion of VANQUISH-2 enrollment, alongside VANQUISH-1, is a key operational step for the company, although investors acknowledge both the significant upside potential and the execution risks associated with increased R&D spending and reliance on cash reserves.
Viking Therapeutics (Nasdaq:VKTX) - Stock Analysis
This report provides a comprehensive stock analysis of Viking Therapeutics (Nasdaq:VKTX), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. The company, with a market cap of US$4.0b, is considered significantly undervalued by analysts, trading at an intrinsic discount of 63.4%. Key developments include ongoing clinical trials for its lead drug candidates, particularly VK2735 for obesity, and recent insider stock sales.
Viking Therapeutics, Inc. (VKTX) stock price, news, quote and history
This article provides comprehensive financial data and company information for Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company. It covers stock price performance, key financial metrics, analyst ratings, and an overview of their drug development pipeline for metabolic and endocrine disorders. The company's stock shows significant long-term growth despite recent fluctuations.
Viking Therapeutics, Inc. (VKTX) interactive stock chart
This Yahoo Finance page provides an interactive stock chart for Viking Therapeutics, Inc. (VKTX), showing its current trading price, performance, and related news. The stock closed at $34.80, up 5.58% on April 2nd, and was trading slightly down after hours. The page also lists recent news articles concerning the company's obesity drug trials and market performance.
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner
Viking Therapeutics (VKTX) stock rose over 2% after CNBC's Fast Money suggested it could be a buyout target this year as big pharma companies compete in the rapidly expanding GLP-1 obesity market. Traders noted that acquisitions are a primary strategy for drugmakers to secure advanced weight-loss therapy pipelines, with Viking's experimental obesity therapy VK2735 advancing through Phase 3 trials and planned late-stage testing for its oral formulation. Investor sentiment on Stocktwits for VKTX has shifted to 'neutral' from 'bullish' amidst a significant increase in message volume.
VKTX Technical Analysis | Trend, Signals & Chart Patterns | VIKING THERAPEUTICS INC (NASDAQ:VKTX)
This article provides a technical analysis of VIKING THERAPEUTICS INC (VKTX), detailing its technical rating, trend indicators, and chart patterns. VKTX has an overall technical rating of 7 out of 10 and an excellent setup rating of 8, with recent price consolidation and identified support and resistance zones. The analysis includes various technical indicators such as SMA, RSI, MACD, and ADX, offering insights into its current market behavior and potential trading setups.
Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today
Viking Therapeutics (NASDAQ: VKTX) has significantly outperformed the market over the last decade with an annualized return of 37.53%. An initial investment of $100 in VKTX 10 years ago would now be worth $2,210.40, demonstrating the power of compounded returns. The company currently holds a market capitalization of $3.81 billion.
Viking Therapeutics (VKTX) stock has failed to impress since Jim Cramer expressed caution
Viking Therapeutics (VKTX) stock has not performed well since Jim Cramer expressed caution about the company. The article suggests that Cramer's warning may have influenced investor sentiment, leading to a lack of upward movement in VKTX shares. This indicates that analyst opinions can significantly impact stock performance.
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages
Viking Therapeutics, Inc. (NASDAQ:VKTX) has received a consensus "Moderate Buy" recommendation from fourteen research firms, with an average 12-month price target of $87.80. The company's stock is trading near $33, with a market capitalization of approximately $3.8 billion, and has seen recent insider selling totaling about $12.05 million over the last 90 days. Despite a recent earnings per share miss, analysts forecast a -$1.56 EPS for the current year.
[DEF 14A] Viking Therapeutics, Inc. Definitive Proxy Statement
Viking Therapeutics, Inc. has filed its definitive proxy statement (DEF 14A) for its virtual 2026 Annual Meeting of Stockholders, scheduled for May 19, 2026. Stockholders will vote on electing two Class II directors, ratifying CBIZ CPAs P.C. as the 2026 auditor, and an advisory approval of executive compensation. The proxy statement details the meeting agenda, voting procedures, board structure, committee responsibilities, director independence, and executive compensation plans.
[ARS] Viking Therapeutics, Inc. SEC Filing
Viking Therapeutics, Inc. (VKTX) has submitted an ARS filing, which is essentially an annual report to shareholders. The filing was accepted on April 1, 2026, at 4:16 PM UTC, and is categorized as having a low filing impact and neutral sentiment. Investors can view the full PDF document on SEC EDGAR.
A Look At Viking Therapeutics (VKTX) Valuation As VANQUISH 2 Enrollment Milestone Advances VK2735 Program
Viking Therapeutics (VKTX) has completed patient enrollment for its Phase 3 VANQUISH-2 trial of VK2735, a dual GLP-1/GIP agonist for obesity and type 2 diabetes. Despite recent share price volatility, the company is seen as significantly undervalued by Simply Wall St's narrative fair value of $92.72, compared to its current price of $32.54. This valuation hinges on the future potential of its obesity franchise, though risks include high R&D spending and reliance on VK2735.
Viking Therapeutics, Inc. (VKTX) Falls Further Than the Overall Market: What Investors Should Know
Viking Therapeutics (VKTX) stock recently dropped 7.95%, underperforming the broader S&P 500. Analysts anticipate a significant loss per share for the upcoming earnings report and the full fiscal year. The company holds a Zacks Rank of #3 (Hold) within a Medical - Biomedical and Genetics sector that is ranked in the bottom 39% of industries.
The Bull Case For Viking Therapeutics (VKTX) Could Change Following Full VK2735 Phase 3 Enrollment Progress
Viking Therapeutics has completed patient enrollment for its Phase 3 VANQUISH-2 trial of VK2735 for obesity and type 2 diabetes. This milestone advances VK2735 further into late-stage development, reinforcing Viking's position in the GLP-1/GIP obesity treatment market. The article discusses how this development may impact Viking's investment narrative, financial forecasts, and various analyst perspectives on the company's future.
Viking Therapeutics (VKTX) Stock Has Failed To Impress Since Jim Cramer Expressed Caution
Viking Therapeutics (VKTX) stock has not performed well since Jim Cramer expressed caution, despite being one of his "Hottest GLP-1 and Weight Loss Stock Picks." The shares are up 34% over the past year but are slightly down since Cramer's January 28 discussion. This underperformance is largely attributed to a 42% drop in August 2025 following the release of mid-stage trial results for its weight-loss drug, VK-2735, which saw participants lose 12% of body weight, falling short of investor expectations.
Viking Therapeutics moves closer to challenging Ozempic with phase 3 trial progress
Viking Therapeutics is advancing its GLP-1 drug, VK2735, as a potential challenger to existing weight-loss medications like Ozempic, with its phase 3 trial nearing commencement. The company recently presented positive phase 2 results showing significant weight loss and a favorable safety profile. These developments position Viking to potentially enter a highly competitive and lucrative market.
Viking Therapeutics: A Small Biotech Firm Competing in the $100B GLP-1 Market - News and Statistics
Viking Therapeutics, a smaller biotechnology firm, is positioning itself as a competitor in the rapidly growing GLP-1 weight loss drug market, which is projected to reach $100 billion annually. The company's future hinges on the success of its VK2735 drug, currently in phase 3 clinical trials for an injectable version and with an oral version entering phase 3 trials later this year. Positive trial results could significantly boost its stock value and potentially make it an acquisition target.
The Bull Case For Viking Therapeutics (VKTX) Could Change Following Full VK2735 Phase 3 Enrollment Progress
Viking Therapeutics has completed patient enrollment for its Phase 3 VANQUISH-2 trial of VK2735, an obesity and type 2 diabetes treatment, reinforcing the potential of its drug pipeline. This milestone, following earlier positive Phase 2 data, could significantly reshape investor perception and move the company closer to an approved drug. However, the high R&D spend and pre-revenue status present ongoing risks.
Viking Therapeutics Trial Milestone Highlights VK2735 And Valuation Gap
Viking Therapeutics has completed patient enrollment in its Phase 3 VANQUISH-2 trial for VK2735, a dual GLP-1/GIP agonist for obesity and type 2 diabetes. This milestone advances VK2735 in the clinical pipeline, drawing attention to its potential in a competitive market. Despite having no revenue and being loss-making, Viking's stock trades significantly below analyst targets and its estimated fair value.
Vanguard disaggregates holdings; reports 0 shares in Viking (VKTX)
The Vanguard Group filed an amended Schedule 13G (Amendment No. 3) for Viking Therapeutics Inc (VKTX), reporting 0 beneficially owned shares and 0% ownership due to an internal realignment effective January 12, 2026. This realignment, referencing SEC Release No. 34-39538, means certain Vanguard subsidiaries will now report their beneficial ownership separately. The filing clarifies that The Vanguard Group itself no longer retains beneficial ownership over securities held by these disaggregated subsidiaries.
VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug
Viking Therapeutics (VKTX) has completed enrollment for its phase III VANQUISH-2 study for its investigational obesity drug VK2735 subcutaneous formulation, enrolling nearly 1,000 adults with type II diabetes who are obese or overweight. This milestone follows the earlier completion of enrollment for the VANQUISH-1 study, indicating strong interest in the drug and rapid progress. The company anticipates completing both VANQUISH studies next year and is also advancing an oral version of VK2735 into late-stage development, as the obesity market grows increasingly competitive with major players like Eli Lilly and Novo Nordisk.
Viking Therapeutics (NASDAQ:VKTX) Now Covered by Wolfe Research
Wolfe Research initiated coverage of Viking Therapeutics (NASDAQ:VKTX) with a "peer perform" rating. This decision contributes to a mixed but generally positive analyst sentiment, with a consensus "Moderate Buy" rating and a price target of $87.80. The article also notes recent insider selling by CEO Brian Lian and other insiders, along with the company's recent earnings miss.
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress
Viking Therapeutics announced the completion of enrollment for its Phase 3 VANQUISH-2 trial of VK2735, an obesity drug designed to compete with popular GLP-1 medications like Ozempic and Wegovy. The study will assess the efficacy and safety of a once-weekly subcutaneous injection of VK2735, with primary endpoints focusing on body weight percentage change over 78 weeks. Viking expects to complete these VANQUISH studies by 2027 and will release results from an ongoing maintenance dosing study in Q3 2026.
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
Viking Therapeutics has announced the completion of enrollment for its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, a dual GLP-1/GIP receptor agonist, for the treatment of obesity in adults with type 2 diabetes. This 78-week, randomized, double-blind, placebo-controlled study enrolled approximately 1,000 patients and aims to evaluate the drug's efficacy and safety, with primary endpoints focusing on body weight reduction. This milestone follows the completed enrollment of the companion VANQUISH-1 study and suggests momentum for new obesity treatment options.
Why Shares of Viking Therapeutics, Inc. (VKTX) Fell More Sharply Than the Overall Market Today
Viking Therapeutics (VKTX) shares experienced a sharper decline than the broader market, falling 1.17% against the S&P 500's 0.37% drop. Investors are closely watching the company as it approaches its earnings report, with analysts expecting a significant year-over-year decrease in earnings per share. Despite a smaller loss over the last month compared to its sector, its 5.54% decline still outpaced the S&P 500's decrease.
Meadowbrook Wealth Management LLC Invests $1.31 Million in Viking Therapeutics, Inc. $VKTX
Meadowbrook Wealth Management LLC acquired a new position of 37,205 shares, valued at approximately $1.31 million, in Viking Therapeutics, Inc. during the fourth quarter, making it the 17th largest holding in their portfolio. Analysts have a consensus "Moderate Buy" rating with a price target of $87.80, indicating potential upside from the current share price in the low-$30s. The article also notes mixed insider activity and highlights key news stories impacting Viking Therapeutics, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders.
Assessing Viking Therapeutics (VKTX) Valuation As Clinical Pipeline Progress Shapes Investor Expectations
Viking Therapeutics (VKTX) is attracting investor interest due to its clinical-stage pipeline, particularly lead candidate VK2809 for non-alcoholic steatohepatitis. Despite its current share price of US$32.17, analysts suggest it could be significantly undervalued with a fair value of $92.72, signaling a potential buying opportunity. This bullish outlook, however, depends on successful trial completion and managing R&D funding without substantial shareholder dilution.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
Viking Therapeutics, Inc. (VKTX) experienced a 1.17% dip, closing at $32.17, underperforming the S&P 500 and Nasdaq, though it lagged behind the Dow's loss. Over the past month, VKTX shares depreciated by 5.54%. Analysts project earnings of -$1.01 per share for the upcoming report and anticipate a full-year revenue of $0 million.
Why Shares of Viking Therapeutics, Inc. (VKTX) Fell More Sharply Than the Overall Market Today
Viking Therapeutics (VKTX) experienced a sharper decline than the overall market, falling 1.17% compared to the S&P 500's 0.37% dip. Over the past month, the stock has decreased by 5.54%, underperforming the S&P 500 but doing better than its sector. The company is preparing to release an earnings report, with analysts expecting a significant year-over-year loss per share.
HC Wainwright Reiterates "Buy" Rating for Viking Therapeutics (NASDAQ:VKTX)
HC Wainwright has reiterated a "Buy" rating for Viking Therapeutics (NASDAQ:VKTX) with a $102 price target, suggesting a potential upside of approximately 215.5%. The biotechnology company currently holds a "Moderate Buy" consensus rating from analysts. Recent insider activity includes a purchase by Neil William Aubuchon and a significant sale by CEO Brian Lian, while institutional investors own about 76% of the stock.
Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics?
This article compares investing $1,500 in Bitcoin versus Viking Therapeutics, highlighting the distinct risks and potential rewards of each. Viking Therapeutics has a promising obesity drug candidate, VK2735, currently in phase 3 trials, but faces stiff competition in a crowded market. Bitcoin offers growth through supply constraints and increasing demand via ETFs but remains highly volatile and exposed to market sentiment.
Viking Therapeutics: Phase 3 Obesity Data Feels Like A Coin Toss (Rating Downgrade) (VKTX)
Viking Therapeutics is advancing VK2735, a dual GLP-1/GIP agonist, with ongoing and planned Phase 3 obesity trials supported by a strong cash position and new manufacturing agreements. Despite promising early efficacy and safety data, the author downgrades VKTX from Buy to Hold due to intensifying market competition and the inherent binary risk associated with Phase 3 clinical trial results. Investors are advised to await Q3 Phase 1 maintenance data before making further decisions.
VIKING THERAPEUTICS, INC. (VKTX)
The article provides a brief overview for VIKING THERAPEUTICS, INC. (VKTX) with no additional content.
Viking Therapeutics, Inc. (VKTX) suffers a larger drop than the general market: Key insights
This article analyzes Viking Therapeutics, Inc.'s stock performance, noting its recent underperformance compared to the broader market. It would typically delve into reasons behind the drop, such as company-specific news, sector trends, or general market conditions, and likely provide financial insights and outlooks.
Viking Therapeutics, Inc. (VKTX) Outperforms the Market: Key Points to Note
Viking Therapeutics (VKTX) recently saw its stock price increase by 1.07% to $36.01, surpassing the S&P 500's daily gain and significantly outperforming its sector over the past month. The company is anticipated to report an EPS of -$1.01 for the upcoming quarter and holds a Zacks Rank of #3 (Hold), with analysts observing upward revisions in EPS estimates. Investors are encouraged to monitor analyst updates and industry performance within the Medical - Biomedical and Genetics sector.
Viking Therapeutics, Inc. (VKTX) Outperforms the Market: Key Points to Note
Viking Therapeutics (VKTX) recently saw its share price increase by 1.07%, outperforming the S&P 500. The stock has surged 22.86% over the past month, significantly outpacing its sector and the broader market. The company is approaching its earnings release, with analysts expecting an EPS of -$1.01 for the quarter and a Zacks Rank of #3 (Hold).
Granahan Investment Management LLC Sells 115,562 Shares of Viking Therapeutics, Inc. $VKTX
Granahan Investment Management LLC reduced its stake in Viking Therapeutics (NASDAQ:VKTX) by 37.9% in the 3rd quarter, selling 115,562 shares and holding 189,529 shares valued at $4.98 million. This comes amidst other institutional investors adjusting their positions and company insiders, including CFO Greg Zante and CEO Brian Lian, selling significant amounts of stock. Analyst ratings for Viking Therapeutics are mixed, with a consensus of "Moderate Buy" and a target price of $87.80.
Baker BROS. Advisors LP Acquires New Shares in Viking Therapeutics, Inc. $VKTX
Baker BROS. Advisors LP has initiated a new stake in Viking Therapeutics (NASDAQ:VKTX) by purchasing 366,083 shares valued at approximately $9.62 million. Other institutional investors like Ameriprise, Two Sigma, and Norges Bank also increased their holdings, leading to institutional ownership of about 76.03%. Despite significant insider selling over the past 90 days, analysts maintain a "Moderate Buy" rating for Viking Therapeutics with an average target price of $87.80.
Viking Therapeutics (VKTX) Valuation Check As Obesity Drug VK2735 Advances Into Phase 3 Trials
Viking Therapeutics (VKTX) is under investor scrutiny as its obesity drug VK2735 progresses into Phase 3 trials, with enrollment nearing completion for both subcutaneous and oral formulations. Despite a significant share price increase over the last year, the company is still considered undervalued by a common valuation narrative, with a fair value of $92.72 against a close of $35.63. The article highlights the potential for future earnings growth due to flexible treatment options but also warns about clinical stage risks and dependence on VK2735’s Phase 3 outcomes.
Viking Therapeutics (VKTX) Valuation Check As Obesity Drug VK2735 Advances Into Phase 3 Trials
Viking Therapeutics (VKTX) is under valuation scrutiny as its obesity drug VK2735 progresses into Phase 3 trials, with enthusiasm building around its potential given recent strong share price performance and the completion of patient enrollment for key studies. Despite a significant share price increase, the most popular valuation narrative suggests the company is 61.6% undervalued, with a fair value of $92.72 compared to its current price of $35.63. However, investors are cautioned to consider the inherent risks associated with its clinical stage status, net loss of US$359.6 million, and heavy reliance on the success of VK2735.
Why Viking Therapeutics (VKTX) Is Up 12.6% After Fast-Tracking VK2735 Into Late-Stage Obesity Trials - And What's Next
Viking Therapeutics has advanced its obesity drug VK2735 into late-stage trials for both injectable and oral formulations, bolstering its position in the obesity treatment market. This acceleration emphasizes the importance of upcoming clinical trial readouts for the company's future, as its investment narrative heavily relies on VK2735's success. While offering significant upside, this strategy also carries substantial risk due to the company's ongoing losses and dependence on its cash reserves.
Viking Therapeutics Phase 3 Obesity Move Tests VK2735 Valuation Gap
Viking Therapeutics has moved its obesity drug candidate VK2735 into Phase 3 development for subcutaneous administration, with enrollment nearly complete. The company has also initiated a maintenance and transition study for the oral version of VK2735, with results expected this year. This progress aims to clarify the drug's regulatory path and potential for partnerships, addressing its current valuation gap despite being a clinical-stage company with no revenue.
Why Has Viking Therapeutics (VKTX) Increased by 16.3% Since Its Previous Earnings Announcement?
Viking Therapeutics (VKTX) shares have increased by 16.3% since its last earnings report, despite reporting wider losses and no revenue for Q4 2025. This rise is attributed to market response, even as analyst estimates for VKTX have trended downward, leading to a Zacks Rank #3 (Hold). The article compares VKTX's performance with Illumina (ILMN), which showed revenue growth and positive earnings.
Jefferies Maintains Buy on Viking Therapeutics, Inc. (VKTX) March 2026
Jefferies has reiterated a "Buy" rating on Viking Therapeutics, Inc. (VKTX) as of March 12, 2026, indicating continued confidence in the company's operational execution without issuing a new price target. The market reaction was minimal, with the stock moving by -0.06%, suggesting that investors are awaiting new data or milestones. Meyka AI currently rates VKTX with a 'B' grade, reflecting broader market comparisons and growth metrics, advising investors to monitor upcoming catalysts.
Viking Therapeutics Phase 3 Obesity Move Tests VK2735 Valuation Gap
Viking Therapeutics has advanced its obesity drug candidate VK2735 into Phase 3 clinical trials, known as VANQUISH-1 and VANQUISH-2, with enrollment nearing completion. The company is also conducting a maintenance and transition study for an oral version of VK2735, with results anticipated later this year. This strategic move highlights Viking's focus on metabolic disorders and positions it in the competitive weight loss drug market, emphasizing clinical progress as a key factor for investors given the company's current valuation, analyst targets, and its pre-revenue status.
Can Viking Therapeutics Capitalize on Weight Loss Drugs for a Comeback?
Viking Therapeutics (VKTX) saw its stock rebound by 16.5% in February, driven by progress in its weight loss drug pipeline, particularly VK2735. The company is addressing past concerns about its oral formulation's side effects and plans to advance oral VK2735 into Phase III trials in Q3 2026, while also progressing with subcutaneous VK2735. The future success of Viking Therapeutics hinges on positive clinical data, offering significant upside potential but also considerable risk for investors.
Viking Therapeutics (VKTX) CCO buys 4,475 shares at $33.50
Viking Therapeutics' Chief Commercial Officer, Neil William Aubuchon, recently purchased 4,475 shares of the company's common stock at a price of $33.50 per share through an open-market transaction. This transaction was reported via an SEC Form 4 filing and increased his direct holdings to 4,475 shares. The filing indicates a positive sentiment regarding the insider's confidence in the company.
Viking Therapeutics (NASDAQ:VKTX) Insider Acquires $149,912.50 in Stock
Viking Therapeutics (NASDAQ:VKTX) director Neil William Aubuchon recently purchased 4,475 shares of the company's stock for $149,912.50, increasing his position significantly. The company's stock traded up 3.1% following the insider buy, despite a recent earnings miss. Analysts currently rate VKTX as a "Moderate Buy" with an average price target of $87.80.
